Navigation Links
Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:12/13/2007

OXFORD, England, Dec. 13 /PRNewswire/ -- Chroma Therapeutics Limited, one of the UK's leading pre-IPO biotechnology companies, announced today positive data from a Phase I study with its oral, once-daily experimental cancer therapy CHR-2797 in the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM) who have failed on, or who are unsuitable for, chemotherapy.

Headline data from the study, which was presented by a key study investigator, Dr. Faith Davies of the Royal Marsden Hospital, London, were as follows:

-- 3 out of 13 AML patients treated in this study showed a complete

response (CR) and one further AML patient became

transfusion-independent;

-- one MM patient (out of two treated in this study) remained in stable

disease after six months of treatment with CHR-2797; and

-- the drug was very well-tolerated during the study

Chroma is currently assessing CHR-2797 in AML and MDS patients in the Phase II portion of this trial. This trial is now fully recruited and results are expected in the first half of 2008.

Ian Nicholson, Chief Executive Officer of Chroma, commented: "We are very encouraged by the efficacy we have seen in this Phase I study and look forward to further exploring how patients with this debilitating disease might be treated with CHR-2797".

An abstract of the data from this study was submitted to the recent American Society of Hematology (ASH) meeting and was subsequently selected for oral presentation. The full ASH presentation will be available at the company's website, http://www.chromatherapeutics.com.

Enquiries

Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles +44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.


'/>"/>
SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) announced ... operating results on Monday, August 7, 2017 after market ... p.m. ET. Shareholders ... of the conference call by dialing 877-201-0168 or 647-788-4901 ... 15 minutes prior to the call. A live webcast ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017  IBM ... of Alberta in Edmonton, Canada ... journal, Schizophrenia 1 , demonstrating that AI and ... with 74% accuracy. This retrospective analysis also showed ... in schizophrenia patients with significant correlation, based on ...
(Date:7/21/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before the market opens on Thursday, July ... Therapeutics will host a teleconference on Thursday, July 27, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 2017 , ... Peruvian Ayahuasca retreat, East West Lodge, announced ... and divided between two full-time university students enrolled in U.S. or Canadian accredited ... apply for the scholarship, students are asked to submit an essay between 750 ...
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum in ... take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland Rockside ... a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is sponsored ...
(Date:7/24/2017)... ... , ... Every year, thousands of dedicated Higher Education and K12 professionals flock ... coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to take ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured ...
(Date:7/24/2017)... CA (PRWEB) , ... July 24, 2017 , ... ... financial organizations, today announced it has partnered with WALLIX to expand its ... Publication 800-171 . , There are a number of ways to address the authentication ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly Topical ... Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... term skin conditions, including cancer. In the short term, overexposure to sun, ...
Breaking Medicine News(10 mins):